Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.60 |
| ▸ | CA1 | P00915 | 9/20 | 0.59 |
| ▸ | CA2 | P00918 | 9/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705078 | 0.96 | GPBAR1 (0.60) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL23705077 | 0.96 | GPBAR1 (0.60) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL26424127 | 0.95 | GPBAR1 (0.59) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL30103321 | 0.95 | CA1 (0.65) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL23710363 | 0.95 | CA1 (0.65) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL23710376 | 0.93 | GPBAR1 (0.57) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL23710338 | 0.92 | GPBAR1 (0.58) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL23705032 | 0.92 | GPBAR1 (0.58) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL23705034 | 0.92 | GPBAR1 (0.58) | GPBAR1CA1CA2MAPTMEN1 | |
| SCHEMBL26086519 | 0.90 | CA1 (0.64) | GPBAR1CA1CA2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4097119-B1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | UNIV JOHNS HOPKINS (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| EP-4097119-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | The Johns Hopkins University (US) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | GPBAR1 2/4885CA1 3966/4885CA2 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.